Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125319321 | 12531932 | 1 | I | 20140528 | 20160706 | 20160706 | EXP | NO-PFIZER INC-2381267 | PFIZER | FOSSA A.. MULTIMODAL TREATMENT WITH ALL-LIKE CHEMOTHERAPY, AUTO-SCT AND RADIOTHERAPY FOR LYMPHOBLASTIC LYMPHOMA. ACTA ONCOL. 2014;53(5):680-687 | 30.00 | YR | M | Y | 0.00000 | 20160706 | OT | NO | NO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125319321 | 12531932 | 1 | PS | PREDNISOLONE. | PREDNISOLONE | 1 | U | 0 | |||||||||||
| 125319321 | 12531932 | 2 | SS | PREDNISONE. | PREDNISONE | 1 | Intrathecal | 10 MG, UNK | UNK | 0 | 10 | MG | |||||||
| 125319321 | 12531932 | 3 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | 40 MG/M2, UNK | UNK | 0 | 40 | MG/M**2 | |||||||
| 125319321 | 12531932 | 4 | C | VINCRISTINE SULFATE. | VINCRISTINE SULFATE | 1 | Intravenous (not otherwise specified) | 1.5 MG/M2, MAX 2.0 MG | UNK | 0 | 1.5 | MG/M**2 | |||||||
| 125319321 | 12531932 | 5 | C | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | 750 MG/M2, UNK | UNK | 0 | 750 | MG/M**2 | |||||||
| 125319321 | 12531932 | 6 | C | CYTARABINE. | CYTARABINE | 1 | Intrathecal | 40 MG, UNK | UNK | 0 | 40 | MG | |||||||
| 125319321 | 12531932 | 7 | C | CYTARABINE. | CYTARABINE | 1 | Intravenous (not otherwise specified) | 200 MG/M2, UNK | UNK | 0 | 200 | MG/M**2 | |||||||
| 125319321 | 12531932 | 8 | C | DAUNORUBICIN | DAUNORUBICIN | 1 | Intravenous (not otherwise specified) | 50 MG/M2, UNK | UNK | 0 | 50 | MG/M**2 | |||||||
| 125319321 | 12531932 | 9 | C | DOXORUBICIN | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 30 MG/M2, UNK | UNK | 0 | 30 | MG/M**2 | |||||||
| 125319321 | 12531932 | 10 | C | G-CSF | GRANULOCYTE COLONY-STIMULATING FACTOR NOS | 1 | 10 MCG/KG/DAY | UNK | 0 | ||||||||||
| 125319321 | 12531932 | 11 | C | L-ASPARAGINASE | ASPARAGINASE | 1 | Intravenous (not otherwise specified) | 10000 IU, UNK | UNK | 0 | 10000 | IU | |||||||
| 125319321 | 12531932 | 12 | C | MERCAPTOPURINE. | MERCAPTOPURINE | 1 | Oral | 35 MG/M2, UNK | UNK | 0 | 35 | MG/M**2 | |||||||
| 125319321 | 12531932 | 13 | C | METHOTREXATE. | METHOTREXATE | 1 | Intrathecal | 15 MG, UNK | UNK | 0 | 15 | MG | |||||||
| 125319321 | 12531932 | 14 | C | METHOTREXATE. | METHOTREXATE | 1 | Intravenous (not otherwise specified) | 1500 MG/M2, UNK | UNK | 0 | 1500 | MG/M**2 | |||||||
| 125319321 | 12531932 | 15 | C | THIOGUANINE | THIOGUANINE | 1 | Intravenous (not otherwise specified) | 150 MG/M2, UNK | UNK | 0 | 150 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125319321 | 12531932 | 2 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 4 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 5 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 6 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 8 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 9 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 10 | Peripheral blood stem cell apheresis |
| 125319321 | 12531932 | 11 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 12 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 13 | Precursor T-lymphoblastic lymphoma/leukaemia |
| 125319321 | 12531932 | 15 | Precursor T-lymphoblastic lymphoma/leukaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125319321 | 12531932 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125319321 | 12531932 | Osteonecrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |